🟢 Abcellera Biologics is trading 5.9% up today after ABCL635 study meets both primary endpoints

Abcellera Biologics is trading 5.9% up now at $9.89 after positive Phase 2 results for ABCL635, its investigational menopause treatment.

• The study met both primary efficacy endpoints, with an 83% reduction in moderate-to-severe hot-flash frequency versus 33% for placebo.
• Results also improved symptom severity and sleep.
• Reuters reported the data sent shares sharply higher on August 10, supporting continued momentum on August 11.